> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Jazz sBLA for Mon./Wed./Fri. Rylaze Dosing
- URL: https://www.fdaweb.com/fda-oks-jazz-sbla-for-mon-wed-fri-rylaze-dosing/
- Published: 2022-11-21T12:00:00.000Z
- Updated: 2026-09-14T18:07:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153243

FDA has approved a Jazz Pharmaceuticals supplemental BLA to add a Monday/Wednesday/Friday (MWF) intramuscular dosing schedule for Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn). The therapy is approved for use as a component of a multi-agent chemotherapeutic regimen for treating acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients one month or older who have developed hypersensitivity to *E. coli*\-derived asparaginase.

The MWF dosing option was approved based on data from the intramuscular administration part of the Phase 2/3 trial (JZP458-201 or AALL1931), according to the company. “Results show that a dosing regimen of 25 mg/m2 administered intramuscularly on Monday morning and Wednesday morning, and 50 mg/m2 administered on Friday afternoon demonstrated a positive benefit-to-risk profile,” it says.